Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30678236 | 1.00 | MAOB (0.66) | MAOBNR4A2KMT2ASMPD1SRD5A2 | |
| SCHEMBL5605259 | 0.90 | SMPD1 (0.65) | MAOBNR4A2KMT2ASMPD1MRGPRX4 | |
| SCHEMBL5744375 | 0.88 | SLC2A1 (0.54) | MAOBNR4A2KMT2ASMPD1MAOA | |
| SCHEMBL5605085 | 0.88 | MAOB (0.68) | MAOBNR4A2KMT2ASMPD1MRGPRX4 | |
| SCHEMBL5604959 | 0.86 | SMPD1 (0.63) | MAOBNR4A2KMT2ASMPD1MAOA | |
| SCHEMBL10466517 | 0.86 | MAOB (0.69) | MAOBNR4A2KMT2ASMPD1SRD5A2 | |
| SCHEMBL5866349 | 0.85 | GPR132 (0.59) | — | |
| SCHEMBL25720520 | 0.85 | FFAR1 (0.53) | MAOBKMT2ASMPD1MRGPRX4MAOA | |
| SCHEMBL1034311 | 0.85 | MAOB (0.63) | MAOBNR4A2KMT2ASRD5A2MEN1 | |
| SCHEMBL20103340 | 0.83 | KMT2A (0.49) | MAOBNR4A2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC (KR) | 2024-08-08 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4342895-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-03-27 | — | — | EP | disclosed |
| EP-4335847-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2024-03-13 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005068452-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IGF-IR INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005040153-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085473-A1 | Novel triarylimidazoles | HOFFMANN-LA ROCHE INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
| WO-2002022584-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085473-A1 | Novel triarylimidazoles | AURKAIP1, GLS2, GOT2 | MAOB 1708/4885NR4A2 1677/4885KMT2A 2396/4885 |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 1885/4885NR4A2 1988/4885KMT2A 2221/4885 |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | MAOB 414/4885NR4A2 2261/4885KMT2A 933/4885 |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, ERBB4, ERBB3 | MAOB 3672/4885NR4A2 152/4885KMT2A 990/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | MAOB 1885/4885NR4A2 1988/4885KMT2A 2221/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 3077/4885NR4A2 267/4885KMT2A 2396/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | MAOB 476/4885NR4A2 2155/4885KMT2A 858/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 2014/4885NR4A2 2421/4885KMT2A 2771/4885 |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | MAOB 1885/4885NR4A2 1988/4885KMT2A 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.